

**Minimal Residual Disease (MRD) as a Surrogate Endpoint
in Acute Myeloid Leukemia (AML) Workshop
Meeting Roster
March 4, 2013**

FDA White Oak Campus, Building 31, the Great Room,
White Oak Conference Center
(Rm. 1503), Silver Spring, MD

PANELISTS

Frederick R. Appelbaum, M.D.

Executive Director, Seattle Cancer Care Alliance
Clinical Research Division, Director, Fred Hutchinson Cancer Research Center
Professor, Medical Oncology Division, University of Washington School of Medicine
Seattle, WA

Maria R. Baer, M.D.

Professor of Medicine
Director, Hematologic Malignancies Program
University of Maryland
Greenebaum Cancer Center
Baltimore, MD

Clara D. Bloomfield, M.D.

Distinguished University Professor
William G. Pace III Professor of Cancer Research
Cancer Scholar and Senior Advisor
The Ohio State University
Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

John DiPersio, M.D., Ph.D.

Deputy Director, Alvin J. Siteman Cancer Center
Virginia E. and Samuel J. Golman Endowed
Professor of Oncology; and Chief, Division of Oncology
Washington University School of Medicine
Division of Oncology
Washington University Medical School
St. Louis, MO

Konstanze Döhner, M.D., Ph.D.

Assistant Professor
University Hospital of Ulm
Dept. of Internal Medicine III
Albert-Einstein-Allee 23
Ulm, Germany

**Minimal Residual Disease (MRD) as a Surrogate Endpoint
in Acute Myeloid Leukemia (AML) Workshop
Meeting Roster
March 4, 2013**

FDA White Oak Campus, Building 31, the Great Room,
White Oak Conference Center
(Rm. 1503), Silver Spring, MD

Harry Paul Erba, M.D., Ph.D.

Associate Professor
Department of Internal Medicine at the University of Michigan Health Systems
University of Michigan
Ann Arbor, MI

David Grimwade, M.D., Ph.D.

Professor of Molecular Haematology
London Department of Medical and Molecular Genetics
Division of Genetics & Molecular Medicine
King's College London School of Medicine
London, United Kingdom

Michael Heuser, M.D.

Max Eder Research Group Leader
Head, Molecular Diagnostics
Attending Physician, Hematology,
Hemostasis, Oncology and Stem Cell
Transplantation, Hannover Medical School
Hannover, Germany

Peter Hokland M.D., DMSC

Co-coordinating Professor, Cancer- and Inflammation Centre
Professor of Hematology
Danish MRC professor in Cancer Therapy
Department of Hematology
Arhus University Hospital
Aarhus, Denmark

Michael R. Loken, Ph.D.

President and Laboratory Director
Hematalogics, Inc.
Seattle, Washington

Rich Little, M.D.

Clinical Investigations Branch (CIB)
Head - Hematologic, HIV, and Stem Cell Therapeutics
Cancer Therapy Evaluation Program

**Minimal Residual Disease (MRD) as a Surrogate Endpoint
in Acute Myeloid Leukemia (AML) Workshop
Meeting Roster
March 4, 2013**

FDA White Oak Campus, Building 31, the Great Room,
White Oak Conference Center
(Rm. 1503), Silver Spring, MD

Soheil Meshinchi, M.D., Ph.D.

Associate Professor
University of Washington School of Medicine
Associate Member
Fred Hutchinson Cancer Research Center
Seattle, WA

Gert J. Ossenkoppele, M.D., Ph.D.

Professor of Haematology
VU University Medical Center
Department of Haematology
Amsterdam, The Netherlands

Franklin O. Smith, M.D.

Professor of Medicine and Pediatrics
Clinical Director, University of Cincinnati Cancer Institute
Academic Health Center
Cincinnati, Ohio

Richard M. Stone, M.D.

Professor, Department of Medicine, Harvard Medical School
Clinical Director, Adult Leukemia Program, Dana-Farber Cancer Institute
Associate Physician, Medicine, Brigham And Women's Hospital
Boston, MA

Adriano Venditti

Associate Professor
Hematology
University Tor Vergata
Rome, Italy

Brent Wood, M.D., Ph.D.

Director, Hematopathology Laboratory
Department of Laboratory Medicine
University of Washington

**Minimal Residual Disease (MRD) as a Surrogate Endpoint
in Acute Myeloid Leukemia (AML) Workshop
Meeting Roster
March 4, 2013**

FDA White Oak Campus, Building 31, the Great Room,
White Oak Conference Center
(Rm. 1503), Silver Spring, MD

FDA

Richard Pazdur, M.D.

Director
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

Gregory Reaman, M.D.- Co Chair

Associate Director
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

Ann Farrell, M.D.

Director
Office of Hematology Products
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

Edvardas Kaminskas, M.D.

Deputy Director
Office of Hematology Products
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

Albert Deisseroth, M.D., Ph.D.

Medical Team Leader
Division of Hematology
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

R. Angelo de Claro, M.D.

Medical Team Leader (Acting)
Division of Hematology
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

Patricia Dinndorf, M.D.

Medical Officer
Division of Hematology
Office of Hematology and Oncology Products (OHOP)
Office of New Drugs, CDER, FDA

**Minimal Residual Disease (MRD) as a Surrogate Endpoint
in Acute Myeloid Leukemia (AML) Workshop
Meeting Roster
March 4, 2013**

FDA White Oak Campus, Building 31, the Great Room,
White Oak Conference Center
(Rm. 1503), Silver Spring, MD

Elizabeth Mansfield, Ph.D.

Director, Personalized Medicine Staff
Office of *In vitro* Diagnostic Device Evaluation and Safety (OVI), CDRH, FDA

Gerald Marti, M.D., Ph.D.

Medical Officer and Research –Regulatory Scientist
Cellular and Tissue Therapy Branch
Division of Cellular and Gene Therapies
Center for Biologics Evaluation and Research (CBER), FDA

Mark Rothmann, Ph.D.

Lead Mathematical Statistician
Office of Translational Science
Office of Biometrics/DBV
Office of New Drugs, CDER, FDA